GlassScriptPhysician profile
Fernando Galaviz
NPI 1003532847
$3,245.39
in general payments reported to CMS, 2019-2025
18 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $46.21 · 2023: $718 · 2024: $1,342 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,179 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,178.96 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $692.52 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $561.78 | 2022-2025 | |
| Amgen INC. | $364.84 | 2023-2025 | Evenity, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $287.37 | 2023-2025 | |
| Lilly USA, LLC | $248.31 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $149.70 | 2023-2025 | |
| Glaxosmithkline, LLC. | $132.88 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.78 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $124.30 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $104.71 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $103.31 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Corcept Therapeutics | $98.13 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.85 | 2024-2025 | Jardiance |
| Aimmune Therapeutics, INC. | $64.10 | 2025 | Zenpep |
| Medtronic, INC. | $28.72 | 2023-2025 | Hawkone, Symplicity G3 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $27.22 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $26.13 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.74 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Galaviz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.